Table 1—

Studies included in the analysis

Study[Ref no.]Study duration weeksInclusion criteriaTreatments tested (all administered twice daily) (n)
Symptoms/rescue medicationFEV1/PEFPrevious treatment (dose per day)
A 9 12During 2-week run-in: ≤3 days with ≥12 puffs bronchodilator; during last 7 days of run-in: ≤3 nights with rescue bronchodilatorFEV1 40–85% predBDP 300–500 µg FLU 1000 µg FP 200 µg Salm. 100 µg TCA 600–1000 µgSFC 50/100 µg (92) Salm. 50 µg (92) FP 100 µg (90) PL (82)
B 10 12BDP 550–800 µg FLU 1250–2000 µg FP 500 µg TCA 1100–1600 µgSFC 50/250 µg (84) Salm. 50 µg (88) FP 250 µg (84) PL (93)
C 11 # 24During week before randomisation: total day+night symptom score ≥2 on ≥4 daysFEV1 or PEF 50–85% predBUD 800–1200 µg BDP 800–1200 µg FP 400–600 µgSFC 50/250 µg (180) BUD 800 µg (173)
  • BDP: beclomethasone dipropionate

  • BUD: budesonide

  • FLU: flunisolide

  • FEV1: forced expiratory volume in one second

  • FP: fluticasone propionate

  • PEF: peak expiratory flow

  • PL: placebo

  • % pred: % predicted

  • Salm.: salmeterol

  • SFC: salmeterol/fluticasone propionate combination

  • TCA: triamcinolone acetonide

  • : For patients previously on inhaled corticosteroids; ≥6 puffs for those on Salm

  • #: Quality-of-life analysis only performed in 4 of the 10 participating countries